ProShare Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

ProShare Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	-$15K	–	2184
2022 Q1	$15K	Sell	5 -1	-17%	-$4.3K	﹤0.01%	2189
2021 Q4	$35K	Buy	6 +3	+100%	+$23K	﹤0.01%	2317
2021 Q3	$30K	Sell	3 -2	-40%	-$17.2K	﹤0.01%	1990
2021 Q2	$52K	Buy	+5	New	+$82.2K	﹤0.01%	2357

Other funds holding SEEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's SEEL Position: Q2 2022 in Review

ProShare Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2022, closing a stake of 5 shares — an estimated $15K sold.

ProShare Advisors first reported a position in SEEL in Q2 2021 and held it in 4 quarters. The position peaked at $52K in Q2 2021. 65 funds tracked by Wall St. Rank hold SEEL as of Q2 2022.

ProShare Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
ProShare Advisors sold 5 Seelos Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $15K.
ProShare Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
ProShare Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $52K in Q2 2021.
65 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.